- Home
- UBX vs BRNS Comparison
UBX vs BRNS Comparison
Compare UBX & BRNS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- UBX
- BRNS
- Stock Information
- Founded
- UBX 2009
- BRNS 2016
- Country
- UBX United States
- BRNS United Kingdom
- Employees
- UBX N/A
- BRNS N/A
- Industry
- UBX Biotechnology: Pharmaceutical Preparations
- BRNS Biotechnology: Pharmaceutical Preparations
- Sector
- UBX Health Care
- BRNS Health Care
- Exchange
- UBX Nasdaq
- BRNS Nasdaq
- Market Cap
- UBX 36.9M
- BRNS 43.8M
- IPO Year
- UBX 2018
- BRNS 2021
- Fundamental
- Price
- UBX $1.94
- BRNS $1.00
- Analyst Decision
- UBX Strong Buy
- BRNS Strong Buy
- Analyst Count
- UBX 2
- BRNS 2
- Target Price
- UBX $7.00
- BRNS $3.00
- AVG Volume (30 Days)
- UBX 203.3K
- BRNS 43.4K
- Earning Date
- UBX 04-14-2025
- BRNS 03-19-2025
- Dividend Yield
- UBX N/A
- BRNS N/A
- EPS Growth
- UBX N/A
- BRNS N/A
- EPS
- UBX N/A
- BRNS N/A
- Revenue
- UBX N/A
- BRNS $14,969,000.00
- Revenue This Year
- UBX N/A
- BRNS $1,803.87
- Revenue Next Year
- UBX $33.62
- BRNS N/A
- P/E Ratio
- UBX N/A
- BRNS N/A
- Revenue Growth
- UBX N/A
- BRNS 106.21
- 52 Week Low
- UBX $0.94
- BRNS $0.80
- 52 Week High
- UBX $3.10
- BRNS $4.16
- Technical
- Relative Strength Index (RSI)
- UBX 48.69
- BRNS 46.05
- Support Level
- UBX $1.99
- BRNS $0.96
- Resistance Level
- UBX $2.17
- BRNS $1.15
- Average True Range (ATR)
- UBX 0.22
- BRNS 0.12
- MACD
- UBX -0.05
- BRNS 0.00
- Stochastic Oscillator
- UBX 22.41
- BRNS 16.67
About UBX Unity Biotechnology Inc.
Unity Biotechnology Inc designs therapeutics that prevent, halt, and reverse various diseases of aging. The company focuses on clearing senescent cells, and creating senolytic medicines. Its medicines target vulnerabilities unique to senescent cells to clear those cells from the human body while leaving normal cells unaffected. The firm focuses on age-associated diseases such as osteoarthritis, eye diseases, and pulmonary diseases. Its drug candidates include, UBX1325 is being developed for age-related diseases of the eye, including diabetic macular edema, or DME, UBX2089, which is a circulating hormone primarily produced in the kidneys and choroid plexus of the brain, which is being researched for multiple neurology indications, and UBX2050.
About BRNS Barinthus Biotherapeutics plc
Barinthus Biotherapeutics PLC is a clinical-stage biopharmaceutical company developing novel T cell immunotherapeutic that guide the immune system to overcome chronic infectious diseases, autoimmunity and cancer.